GPT and metabolic dysfunction-associated steatotic liver disease: CYP17A1−/− mice significantly speed up hepatic steatosis or non-alcoholic fatty liver disease (NAFLD) (Additional file 1: Fig. S6B) with higher AST (Additional file 1: Fig. S7C) and ALT (Additional file 1: Fig. S7D), indicating by fat accumulation in the liver (Additional file 1: Fig. S8B).